Title
Retrospective cohort study of anti-tumor necrosis factor agent use in a veteran population.

Permalink
https://escholarship.org/uc/item/52x016nd

Journal
PeerJ, 2(1)

ISSN
2167-8359

Authors
Bounthavong, Mark
Madkour, Nermeen
Kazerooni, Rashid

Publication Date
2014

DOI
10.7717/peerj.385

Peer reviewed
Retrospective cohort study of anti-tumor necrosis factor agent use in a Veteran Population

Mark Bounthavong, Nermeen Madkour and Rashid Kazerooni
Veterans Affairs San Diego Healthcare System, San Diego, CA, USA

ABSTRACT

Introduction. Anti-tumor necrosis factor (TNF) agents are effective for several immunologic conditions (rheumatoid arthritis (RA), Crohn’s disease (CD), and psoriasis). The purpose of this study was to evaluate the efficacy and safety of anti-TNF agents via chart review.

Methods. Single-site, retrospective cohort study that evaluated the efficacy and safety of anti-TNF agents in veterans initiated between 2010 and 2011. Primary aim evaluated response at 12 months post-index date. Secondary aims evaluated initial response prior to 12 months post-index date and infection events.

Results. A majority of patients were prescribed anti-TNF agents for CD (27%) and RA (24%). Patients were initiated on etanercept (41%), adalimumab (40%), and infliximab (18%) between 2010 and 2011. No differences in patient demographics were reported. Response rates were high overall. Sixty-five percent of etanercept patients, 82% of adalimumab patients, and 59% of infliximab patients were either partial or full responders, respectively. Approximately 16%, 11%, and 12% of etanercept, adalimumab, and infliximab were non-responders, respectively. Infections between the groups were non-significant. Etanercept and adalimumab patients had higher but non-significant odds of being a responder relative to infliximab.

Conclusions. Most patients initiated with anti-TNF agent were responders at 12 months follow-up for all indications in a veteran population.

INTRODUCTION

In the past two decades, biologic therapies have reshaped how clinicians approached chronic disease management (Agarwal, 2011a; Agarwal, 2011b; Ford et al., 2011; Lichtenstein, Hanauer & Sandborn, 2009; Mayberry et al., 2013; Singh & Cameron, 2012). Immunologic disorders such as rheumatoid arthritis (RA) and Crohn’s disease (CD) have traditionally relied on oral pharmacotherapy for treatment of acute symptoms, management, and remission. However, oral therapies were unable to provide long-term control and disease progression resulting in relapse and hospital admission/surgery. Biologic agents, such as monoclonal antibodies, target the host’s immune system to attenuate the self-destructive immune response, which is the cause of RA and CD. Clinical
The efficacy with biologics has been reported in RA and CD as well as a reduction in hospital admission/surgery (Bodger, 2002; Lundkvist, Kastång & Kobelt, 2008). More importantly, biologic therapy has improved the quality of life for patients suffering with these chronic diseases (Feagan et al., 2009; Staples et al., 2011).

Monoclonal antibodies, in particular, the anti-tumor necrosis factor (TNF) agents, have demonstrated significant reductions in disease symptoms, progression, and improvement in patient quality of life (Feagan et al., 2009; Ford et al., 2011; Lundkvist, Kastång & Kobelt, 2008; Nixon, Bansback & Brennan, 2007; Ordás, Feagan & Sandborn, 2011). In several studies, anti-TNF agents have increased the proportion of patients who experience remission; thereby, controlling the disease and limiting permanent damage. In some studies, remission duration has been reported for several years (Ançuța et al., 2009; Emery et al., 2010; Van der Heijde et al., 2006).

RA is a systemic autoimmune disorder which is characterized by inflammation of the synovial joints (Segal, Rhodus & Patel, 2008). RA affects about 0.5% to 1.0% of the US population with a prevalence of 1.3 million (Gabriel & Michaud, 2009; Helmick et al., 2008). The health burden of RA in the US was estimated to be 98 Disability Adjusted Life Years (DALYS) lost per 100,000 population; and 1 RA-related death per 100,000 population (Lundkvist, Kastång & Kobelt, 2008). In the VA, there were a total of 1,694 RA-related mortalities from 1999 to 2004 (Lee et al., 2007). The age-adjusted 5-year RA-related mortality rate among patients with a single condition relative to no other condition was 6.05 (95% confidence interval [CI] [4.90, 7.20]) (Lee et al., 2007). The average annual costs of RA per person in the US was $12,558 (adjusted for 2006 $US) (Lundkvist, Kastång & Kobelt, 2008).

The goal of therapy for patients with RA is to control and reduce the rate of degeneration of the joints due to immunologic destruction by the host’s immune system (Agarwal, 2011a). In addition, quality of life and increased productivity are important milestones for treatment. Anti-TNF agents have been reported to reduce the rate of radiographic progression and improve short-term inflammatory symptoms (Bathon et al., 2000; Breedveld et al., 2006; Choy et al., 2012; Emery et al., 2009; Keystone et al., 2008; Keystone et al., 2009; Keystone et al., 2004; Klareskog et al., 2004; Maini et al., 1999; Moreland et al., 1999; St Clair et al., 2004; Van de Putte et al., 2004; Weinblatt et al., 2003; Weinblatt et al., 1999). Consequently, improvement in clinical outcomes has resulted in improved quality of life for RA patients. To date, there are five FDA-approved anti-TNF agents for RA: adalimumab (Humira®), certolizumab pegol (Cimzia®), etanercept (Enbrel®), golimumab (Simponi®), and infliximab (Remicade®) (Agarwal, 2011b).

Crohn's disease is a chronic inflammation of the gastrointestinal tract that is characterized by abdominal pain, diarrhea, gastrointestinal bleeding, bowel perforations, and fistulas (Baumgart & Sandborn, 2012). The incidence of Crohn's disease in the United States (US) was 7.9 cases per 100,000 population (1990–2000); and the adjusted prevalence was 174 per 100,000 population (2001) (Loftus et al., 2007; Loftus, Schoenfeld & Sandborn, 2002). In 2009, the average annual age- and gender-adjusted incidence rate of CD among veterans was 33 per 100,000 population (range: 27–40) (Hou et al., 2013). The age- and
gender-adjusted point prevalence of CD among veterans was 287 per 100,000 population (Hou et al., 2013). Prior to the widespread use of anti-TNF agents, the average annual cost per patient in the US was estimated to be $19,237 (adjusted for 2012 $US) with surgery responsible for a majority of direct costs (55.8%) (Bodger, 2002). However, after the widespread use of anti-TNF agents, the average annual cost per patient with CD was $13,699 per year (adjusted for 2012 $US) (Kappelman et al., 2008).

Biologic therapies, such as anti-TNF agents, for Crohn’s disease have provided clinically meaningful improvement in patient reported outcomes while maintaining remission (Ford et al., 2011; Hanauer et al., 2006; Louis et al., 2013; Sandborn et al., 2007a; Sandborn et al., 2007b). As a result, the increased utilization of anti-TNF therapy has shifted costs from hospitalizations and surgeries to medications. Van der Valk et al. (2012) reported that medication costs were responsible for 70.9% of total direct costs compared to hospitalizations- (19.4%) and surgery-related costs (0.6%) in the Netherlands (Van der Valk et al., 2012). Loomes et al. (2011) reported that total direct costs increased from $3,930 to $25,346 (difference of $21,416, $ < 0.005) after the introduction of infliximab therapy (adjusted for 2010 $CAN) (Loomes et al., 2011). Currently, there are three anti-TNF agents FDA-approved for the treatment and management of CD: adalimumab, certolizumab pegol, and infliximab (FDA Office of the Commissioner, 2008, National Digestive Diseases Information Clearinghouse (NDDIC)).

The Department of Veterans Affairs has a national formulary that is shared with all the VA medical centers around US and its territories. However, none of the anti-TNF agents are listed on the VA National Formulary (VANF) as of August 2013. This is important because the burden of disease in the VA is significant. There have been no reports that currently investigated the efficacy and safety of anti-TNF agents in the veteran population for all indications.

The purpose of this study was to evaluate the efficacy and safety of anti-TNF agent use in the Veterans Affairs San Diego Healthcare System (VASDHS) who initiated therapy in 2010 and 2011 for all prescribed indications. Particular attention was focused on RA and CD due to early approvals in these therapeutic areas.

METHODS
This was a single-site, retrospective cohort study that evaluated the efficacy and safety of anti-TNF agents in a veteran population who initiated treatment between 2010 and 2011 and followed-up for 12 months. The study site was at VASDHS, a 296-bed medical facility in the San Diego County, California with a regional patient membership of approximately 232,000 veterans. VASDHS is part of the Veterans Health Administration (VHA), an integrated healthcare system in the US.

Patients were eligible for inclusion if they were 18 years old or greater and initiated on an anti-TNF agent at VASDHS between 2010 and 2011. The index date was determined to be the first fill-date of the anti-TNF agent at VASDHS.

Clinical efficacy was categorized as responder, partial responder, and non-responder which were determined from chart notes as defined by the provider. Responders were
defined as any documented report of improvement from baseline based on resolution of symptoms and clinical assessment by the provider. Partial responders were defined as any documented report of partial improvement from baseline based on attenuated but continued symptoms and clinical assessment by the provider. Non-responders were defined as any documented report of no improvement from baseline based on continued or worsening of symptoms and clinical assessment by the provider. Two reviewers independently performed the chart reviews (MB and NM) and any disagreements on clinical response were resolved through group discussion.

Primary indication for the anti-TNF agent was determined through the submission of non-formulary (or prior authorization) consults which were reviewed by the VASDHS pharmacy service pharmacoeconomics/formulary group. Anti-TNF agents are listed as non-formulary in the VHA; therefore, requests for these agents in VASDHS require a submission of a non-formulary consult. Providers were required to list the primary indication for anti-TNF agent use. If more than one indication was listed, then the primary indication was categorized according to the specialty field of the submitting provider. For example, a rheumatology provider who submitted a non-formulary consult for both arthritis and psoriasis will have the indication categorized for RA.

Primary aim evaluated response at 12 months post-index date. A majority of clinical trails evaluated response at 12 months; therefore, we also followed this convention. Secondary aims evaluated initial response to anti-TNF agents prior to the 12 months post-index date, alternative strategy after failure to respond or development of an adverse drug event to the initial anti-TNF agent, and infection events. Reporting was further stratified into the top three indications: RA, CD, and psoriasis. Infection events included any infection that occurred after the index date up to 12 months post-index date.

This study received appropriate approvals from the UCSD/VASDHS Institutional Review Board and the Research and Development Committee (Protocol #: H120150).

**Statistical analysis**

Normality testing was performed using Shapiro–Wilk’s test for continuous data. Descriptive analyses for continuous data were presented as mean, standard deviation, and median. Discrete data were presented as frequency and percentage. One-way analysis of variance and Kruskal–Wallis tests were performed for continuous data where appropriate. Pearson’s chi-squared and Fisher’s exact tests were performed for discrete data.

Logistic regression was performed to evaluate the association between anti-TNF agents and response controlling for potential confounders. The outcome variable was transformed into a binary variable in order to perform the logistic regression. Responders and partial responders were collapsed into “Responders”. Non-responder and patients who experienced an adverse drug event were categorized as “Non-responders”. Model fit was assessed using Hosmer–Lemeshow test. Statistical significance was defined as \( P < 0.05 \), two-tailed. All analyses were performed using IBM SPSS Statistics for Windows, Version 20.0 (IBM Corp., Armonk, NY).
RESULTS

Baseline

A total of 92 patients met the inclusion criteria. Table 1 summarizes the demographic variables of the cohort. The average patient was 50 (SD, 16.2) years old, male (N = 77, 84%), non-Hispanic (N = 78, 85%), and white (N = 68, 74%). CD was the most common indication for an anti-TNF agent (N = 25, 27%) followed by RA (N = 22, 24%), psoriasis (N = 19, 21%), psoriatic arthritis (N = 13, 14%), other conditions (N = 8, 9%), and ankylosing spondylitis (N = 5, 5%). The most common comorbid conditions were hypertension (N = 39, 42%), dyslipidemia (N = 36, 39%), gastrointestinal conditions excluding CD (N = 24, 26%), cardiovascular disease (N = 11, 12%), and diabetes (N = 11, 12%). Several patients were on prednisone (N = 18, 20%) or methotrexate (N = 15, 16%) at baseline. Less than half of the study patients had previous experience with an anti-TNF agent (N = 42, 46%), most commonly adalimumab (N = 22) followed by etanercept (N = 11) and infliximab (N = 9).

A majority of patients were started on adalimumab (N = 38) and etanercept (N = 37) followed by infliximab (N = 17) between 2010 and 2011 at VASDHS (Table 2). There were no differences in age (P = 0.141), gender (P = 0.480), ethnicity (P = 0.132), and race (P = 0.726) between the three anti-TNF agents. No difference in primary diagnosis for anti-TNF agent use was reported with RA (P = 0.119), psoriatic arthritis (P = 0.167), ankylosing spondylitis (P = 0.474), and other conditions (P = 0.157) between the three anti-TNF agents. Infliximab and adalimumab were often used in CD compared to etanercept (P < 0.0001). Conversely, a majority of patients received adalimumab to treat psoriasis relative to the other agents (P < 0.0001). There were no statistically significant difference in comorbidities between the three anti-TNF agents except for hypertension (P = 0.023), other gastrointestinal conditions other than CD (P = 0.016), and hypothyroidism (P = 0.020). A majority of patients had tuberculosis screening (N = 83, 90%) and hepatitis B screening (N = 73, 79%) performed at baseline.

At baseline, methotrexate was only reported by patients who started on etanercept (N = 8) and adalimumab (N = 7). A small number of prednisone prescriptions were written at baseline during initiation of etanercept (N = 6), adalimumab (N = 8), and infliximab (N = 4). Among patients who started on etanercept at the VASDHS, six had previous experience with it. Similarly, among patients who were initiated on adalimumab and infliximab at VASDHS, eleven and two patients had a previous history with those agents, respectively.

Clinical response

The average time to first follow-up visit was 86 (SD, 120) days. At the initial follow-up, 73 (83%) patients responded (responder and partial responder) to therapy (Table 3). At 12 months follow-up, a majority of patients responded (responder and partial responder) to therapy (N = 65, 71%). After 12 months of follow-up, there were 15 unique cases (16%) of infections that did not require hospital admissions, and three adverse drug events were reported which resulted in discontinuation of anti-TNF agent therapy. Two of the
| Variable                                             | N  | Mean  | SD   |
|------------------------------------------------------|----|-------|------|
| Age (years)                                          | 92 | 49.97 | 16.23|
| Body mass index (kg/m²)                              |   | 28.96 | 5.49 |
| Aspartate aminotransferase (mg/dL)                   |   | 24.88 | 20.35|
| Alanine aminotransferase (mg/dL)                     |   | 28.13 | 25.71|
| Number                                              |    |       |      |
| Gender                                               |    |       |      |
| Male                                                 | 77 |       | 84%  |
| Female                                               | 15 |       | 16%  |
| Ethnicity                                            |    |       |      |
| Hispanic                                             | 13 |       | 14%  |
| Non-Hispanic                                         | 78 |       | 85%  |
| Unknown                                              | 1  |       | 1%   |
| Race                                                 |    |       |      |
| White                                                | 68 |       | 74%  |
| Black                                                | 11 |       | 12%  |
| Asian                                                | 3  |       | 3%   |
| Native American/Pacific Islander                     | 2  |       | 2%   |
| American Indian/Alaskan Native                       | 1  |       | 1%   |
| Unknown                                              | 5  |       | 5%   |
| Declined                                             | 2  |       | 2%   |
| Primary Diagnosis                                    |    |       |      |
| Rheumatoid arthritis                                 | 23 |       | 25%  |
| Crohn's disease                                      | 24 |       | 26%  |
| Psoriasis                                            | 19 |       | 21%  |
| Psoriatic arthritis                                  | 13 |       | 14%  |
| Other *                                              | 7  |       | 8%   |
| Ankylosing spondylitis                               | 5  |       | 5%   |
| Comorbid conditions                                  |    |       |      |
| Diabetes                                             | 11 |       | 12%  |
| Hypertension                                         | 39 |       | 42%  |
| Arrhythmia                                           | 3  |       | 3%   |
| Heart failure                                        | 3  |       | 3%   |
| Malignancy                                           | 7  |       | 8%   |
| Chronic lung disease                                 | 5  |       | 5%   |
| Cardiovascular disease                               | 11 |       | 12%  |
| Hepatic disease                                      | 3  |       | 3%   |
| Renal                                                | 5  |       | 5%   |
| Gout                                                 | 5  |       | 5%   |
| Hepatitis C                                          | 4  |       | 4%   |
| Dyslipidemia                                         | 36 |       | 39%  |
Table 1 (continued)

| Condition                                | Number | Percent |
|------------------------------------------|--------|---------|
| History of myocardial infarction         | 2      | 2%      |
| Gastrointestinal (other than Crohn’s disease) | 24     | 26%     |
| Hypothyroidism                           | 5      | 5%      |
| Baseline DMARDS                          |        |         |
| Methotrexate                             | 15     | 16%     |
| Prednisone                               | 18     | 20%     |
| Sulfasalazine                            | 9      | 10%     |
| Plaquenil                                | 4      | 4%      |
| Previous anti-TNF agent                  |        |         |
| Yes                                      | 42     | 46%     |
| No                                       | 50     | 54%     |
| Anti-TNF agent history                   |        |         |
| Adalimumab history                       | 22     | 24%     |
| Etanercept history                       | 11     | 12%     |
| Infliximab history                       | 9      | 10%     |
| Anti-TNF agent history origin            |        |         |
| Community provider                       | 21     | 23%     |
| Another VA facility                      | 5      | 5%      |
| Department of Defense                    | 4      | 4%      |
| Veterans Affairs San Diego Healthcare System | 12   | 13%     |
| Rheumatoid factor result at baseline     |        |         |
| Positive                                 | 11     | 12%     |
| Negative                                 | 14     | 15%     |
| Tuberculosis test performed              |        |         |
| Yes                                      | 83     | 90%     |
| No                                       | 9      | 10%     |
| Tuberculosis result                      |        |         |
| Positive                                 | 3      | 3%      |
| Negative                                 | 79     | 86%     |
| Hepatitis test performed                 |        |         |
| Yes                                      | 73     | 79%     |
| No                                       | 19     | 21%     |
| Hepatitis B surface antigen (+)          | 27     | 29%     |
| Hepatitis B surface antibody (+)         | 1      | 1%      |
| Hepatitis C antibody (+)                 | 7      | 8%      |

Notes.
* “Other” includes ulcerative colitis (N = 5), uveitis (N = 1), and spondylarthropathy (N = 1).

drug events that resulted in discontinuation were infection-related (abscess and surgical wound); the other was for myelosplastic syndrome.

At 12 months follow up, there was no significant differences in responses between anti-TNF agents (P = 0.904). In patients initiated on etanercept, 18 (49%) were responders, 6 (16%) were partial responders, 6 (16%) were non-responders, and 2 (5%) had an adverse drug event (myelosplastic syndrome and surgical wound infection) at 12 months (Fig. 1). In patients initiated on adalimumab, 23 (61%) were responders, 8 (21%)
| Variable                              | Etanercept          | Adalimumab         | Infliximab         | P-value |
|--------------------------------------|---------------------|--------------------|--------------------|---------|
| Age (years)                          | 52.92 ± 15.15      | 49.47 ± 15.97      | 44.60 ± 17.69      | 0.141   |
| Body mass index (kg/m²)              | 30.44 ± 6.02       | 28.30 ± 4.92       | 27.02 ± 4.79       | 0.108   |
| Aspartate aminotransferase (mg/dL)   | 28.57 ± 28.06      | 24.00 ± 13.43      | 18.31 ± 6.02       | 0.122   |
| Alanine aminotransferase (mg/dL)     | 33.59 ± 34.75      | 27.92 ± 17.59      | 16.00 ± 5.29       | 0.004   |

| Gender                               | Etanercept          | Adalimumab         | Infliximab         | Chi-square | df  | P-value |
|--------------------------------------|---------------------|--------------------|--------------------|-------------|-----|---------|
| Male                                 | 33 (89%)            | 30 (79%)           | 14 (82%)           | 1.469       | 2   | 0.480   |
| Female                               | 4 (11%)             | 8 (21%)            | 3 (18%)            |             |     |         |

| Ethnicity                            | Etanercept          | Adalimumab         | Infliximab         | Chi-square  | df  | P-value |
|--------------------------------------|---------------------|--------------------|--------------------|--------------|-----|---------|
| Hispanic                             | 4 (11%)             | 8 (21%)            | 1 (6%)             | 7.069        | 4   | 0.132   |
| Non-Hispanic                         | 33 (89%)            | 30 (79%)           | 15 (88%)           |              |     |         |
| Unknown                              | 0 (0%)              | 0 (0%)             | 1 (6%)             |              |     |         |

| Race                                 | Etanercept          | Adalimumab         | Infliximab         | Chi-square  | df  | P-value |
|--------------------------------------|---------------------|--------------------|--------------------|--------------|-----|---------|
| White                                | 29 (78%)            | 25 (66%)           | 14 (82%)           | 8.724        | 12  | 0.726   |
| Black                                | 5 (14%)             | 5 (13%)            | 1 (6%)             |              |     |         |
| Asian                                | 1 (3%)              | 1 (3%)             | 1 (6%)             |              |     |         |
| Native American/Pacific Islander     | 1 (3%)              | 1 (3%)             | 0 (0%)             |              |     |         |
| American Indian/Alaskan Native       | 0 (0%)              | 1 (3%)             | 0 (0%)             |              |     |         |
| Unknown                              | 1 (3%)              | 4 (11%)            | 0 (0%)             |              |     |         |
| Declined                             | 0 (0%)              | 1 (3%)             | 1 (6%)             |              |     |         |
| Primary diagnosis | Etanercept |  | Adalimumab |  | Infliximab |  | Chi-square | df | P-value |
|-------------------|------------|---|------------|---|------------|---|------------|---|---------|
| Number            | Percent    | Number | Percent    |  | Number     | Percent |           |   |         |
| Rheumatoid arthritis | 10        | 27%  | 12         | 32% | 1          | 6%      | 4.272     | 2 | 0.119   |
| Crohn’s disease   | 0          | 0%   | 12         | 32% | 12         | 71%     | 31.113    | 2 | <0.0001 |
| Psoriatic arthritis | 7         | 19%  | 6          | 16% | 0          | 0%      | 3.583     | 2 | 0.167   |
| Ankylosing spondylitis | 3        | 8%   | 2          | 5%  | 0          | 0%      | 1.494     | 2 | 0.474   |
| Psoriasis         | 16         | 43%  | 3          | 8%  | 0          | 0%      | 19.722    | 2 | <0.0001 |
| Other             | 1          | 3%   | 3          | 8%  | 3          | 18%     | 3.708     | 2 | 0.157   |
| Comorbid conditions |           |      |            |    |            |         |           |   |         |
| Diabetes          | 7          | 19%  | 4          | 11% | 0          | 0%      | 4.086     | 2 | 0.130   |
| Hypertension      | 21         | 57%  | 15         | 39% | 3          | 18%     | 7.521     | 2 | 0.023   |
| Arrhythmia        | 1          | 3%   | 2          | 5%  | 0          | 0%      | 1.093     | 2 | 0.579   |
| Heart failure     | 0          | 0%   | 3          | 8%  | 0          | 0%      | 4.407     | 2 | 0.110   |
| Malignancy        | 2          | 5%   | 5          | 13% | 0          | 0%      | 3.32      | 2 | 0.190   |
| Chronic lung disease | 1         | 3%   | 3          | 8%  | 1          | 6%      | 0.991     | 2 | 0.609   |
| Cardiovascular disease | 5       | 14%  | 6          | 16% | 0          | 0%      | 2.924     | 2 | 0.232   |
| Hepatic disease   | 3          | 8%   | 0          | 0%  | 0          | 0%      | 4.61      | 2 | 0.100   |
| Renal disease     | 2          | 5%   | 3          | 8%  | 0          | 0%      | 1.425     | 2 | 0.491   |
| Gout              | 3          | 8%   | 2          | 5%  | 0          | 0%      | 1.494     | 2 | 0.474   |
| Hepatitis C       | 2          | 5%   | 1          | 3%  | 1          | 6%      | 0.465     | 2 | 0.793   |
| Dyslipidemia      | 16         | 43%  | 17         | 45% | 3          | 18%     | 4.058     | 2 | 0.131   |
| History of MI     | 1          | 3%   | 1          | 3%  | 0          | 0%      | 0.464     | 2 | 0.793   |
| GI (other than CD) | 10        | 27%  | 14         | 37% | 0          | 0%      | 8.297     | 2 | 0.016   |
| Hypothyroidism    | 5          | 14%  | 0          | 0%  | 0          | 0%      | 7.86      | 2 | 0.020   |

Baseline DMARDs

| Methotrexate | Prednisone | Sulfasalazine | Plaguenil |
|-------------|------------|---------------|-----------|
| 8           | 6          | 5             | 2         |
| 22%         | 16%        | 14%           | 5%        |
| Methylprednisolone | 6 | 16% | 8 | 21% |
| 24%         | 21%        | 20%           | 19%       |

(continued on next page)
Table 2 (continued)

|                         | Etanercept |            | Adalimumab |            | Infliximab |            | Chi-square | df | P-value |
|-------------------------|------------|------------|------------|------------|------------|------------|------------|----|---------|
|                         | Number     | Percent    | Number     | Percent    | Number     | Percent    |            |    |         |
| Previous TNF agent      |            |            |            |            |            |            |            |    |         |
| Yes                     | 13         | 35%        | 20         | 53%        | 9          | 53%        | 2.76       | 2  | 0.252   |
| No                      | 24         | 65%        | 18         | 47%        | 8          | 47%        |            |    |         |
| Origin                  |            |            |            |            |            |            |            |    |         |
| Community provider      | 8          | 22%        | 9          | 24%        | 4          | 24%        | 3.317      | 6  | 0.768   |
| Another VA facility     | 1          | 3%         | 2          | 5%         | 2          | 12%        |            |    |         |
| DoD                     | 1          | 3%         | 3          | 8%         | 0          | 0%         |            |    |         |
| VASDHS                  | 3          | 8%         | 6          | 16%        | 3          | 18%        |            |    |         |
| RF result at baseline   |            |            |            |            |            |            |            |    |         |
| Positive                | 7          | 19%        | 3          | 8%         | 1          | 6%         | 2.279      | 2  | 0.320   |
| Negative                | 5          | 14%        | 8          | 21%        | 1          | 6%         |            |    |         |
| TB test performed       |            |            |            |            |            |            |            |    |         |
| Yes                     | 35         | 95%        | 33         | 87%        | 15         | 88%        | 1.369      | 2  | 0.504   |
| No                      | 2          | 5%         | 5          | 13%        | 2          | 12%        |            |    |         |
| TB result               |            |            |            |            |            |            |            |    |         |
| Positive                | 1          | 3%         | 1          | 3%         | 1          | 6%         | 0.475      | 2  | 0.789   |
| Negative                | 34         | 92%        | 31         | 82%        | 14         | 82%        |            |    |         |
| Hepatitis test performed|            |            |            |            |            |            |            |    |         |
| Yes                     | 31         | 84%        | 31         | 82%        | 11         | 65%        | 2.784      | 2  | 0.249   |
| No                      | 6          | 16%        | 7          | 18%        | 6          | 35%        |            |    |         |
| HBsAg (+)               | 9          | 24%        | 12         | 32%        | 6          | 35%        | 0.449      | 2  | 0.799   |
| HBsAb (+)               | 1          | 3%         | 0          | 0%         | 0          | 0%         | 1.33       | 2  | 0.514   |
| HCAb (+)                | 5          | 14%        | 2          | 5%         | 0          | 0%         | 2.457      | 2  | 0.293   |

Notes.

GI, gastrointestinal; CD, Crohn’s disease; MI, myocardial infarction; RF, rheumatoid factor; TB, tuberculosis; HBsAg, hepatitis B surface antigen; HBsAb, hepatitis B surface antibody; HCAb, hepatitis C antibody.

* “Other” includes ulcerative colitis (N = 5), uveitis (N = 1), and spondylarthropathy (N = 1).
| All groups | Etanercept | Adalimumab | Infliximab | Chi-square | df | P-value |
|------------|------------|------------|------------|------------|----|---------|
| **Number** | **%**      | **Number** | **%**      | **Number** | **%** |          |
| **Responder** | 65 | 71% | 23 | 62% | 27 | 71% | 15 | 88% | 7.764 | 4 | 0.101 |
| **Partial** | 11 | 12% | 7 | 19% | 4 | 11% | 0 | 0% |          |          |          |
| **Non-responder** | 10 | 11% | 4 | 11% | 6 | 16% | 0 | 0% |          |          |          |
| **Outcome at 12 months** | 49 | 53% | 18 | 49% | 23 | 61% | 8 | 47% | 2.169 | 6 | 0.904 |
| **Responder** | 16 | 17% | 6 | 16% | 8 | 21% | 2 | 12% |          |          |          |
| **Partial** | 12 | 13% | 6 | 16% | 4 | 11% | 2 | 12% |          |          |          |
| **Non-responder** | 3 | 3% | 2 | 5% | 1 | 3% | 0 | 0% |          |          |          |
| **Infections after anti-TNF agent initiation** | 15 | 16% | 5 | 14% | 10 | 26% | 0 | 0% | 6.314 | 2 | 0.043 |
| **Yes** | 77 | 84% | 32 | 86% | 28 | 74% | 17 | 100% |          |          |          |
| **No** | 77 | 84% | 32 | 86% | 28 | 74% | 17 | 100% |          |          |          |

Figure 1 Outcome with tumor necrosis factor use at 12 months, 2010–2011.

were partial responders, 4 (11%) were non-responders, and 1 (3%) had an adverse drug event (abscess) at 12 months. In patients initiated on infliximab, 8 (47%) were responders, 2 (12%) were partial responders, 2 (12%) were non-responders, and 0 had an adverse drug event at 12 months. There were missing data for 5, 2 and 5 patients in the etanercept, adalimumab, and infliximab groups, respectively. These missing data were considered missing completely at random; therefore complete-case analysis was appropriate (Little & Rubin, 2002).

Responders were stratified by RA, CD, and psoriasis for each anti-TNF agent (Fig. 2). In RA, 91% of patients receiving adalimumab were responders compared to 78% with etanercept. In CD, 89% of patients receiving infliximab were responders compared to 73%
with adalimumab. In psoriasis, 100% of patients receiving adalimumab were responders compared to 64% receiving etanercept.

Infections were reported for 5 (14%), 10 (26%), and 0 (0%) patients in the etanercept, adalimumab, and infliximab groups, respectively. This difference in infection rates between all three anti-TNF agents was statistically significant ($P = 0.043$).

Unadjusted odds of being a responder were 0.60 (95% CI [0.11, 3.34]) and 1.24 (95% CI [0.21, 7.41]) for patients initiated on etanercept and adalimumab relative to infliximab, respectively (Table 4). Controlling for age, gender, and previous history of anti-TNF agent use, the odds of being a responder was 0.91 (95% CI [0.13, 6.23]) and 1.85 (95% CI [0.26, 13.10]) for patients initiated on etanercept and adalimumab relative to infliximab, respectively.

Table 4  Odds of responder relative to infliximab.

| Variable                      | B    | SE   | OR   | 95% CI          |
|-------------------------------|------|------|------|-----------------|
| **Crude analysis**            |      |      |      |                 |
| Etanercept                    | −0.511 | 0.876 | 0.60 | 0.108, 3.338    |
| Adalimumab                    | 0.215 | 0.912 | 1.24 | 0.207, 7.412    |
| **Odds of responder adjusted for age, gender, and TNF history relative to infliximab** |      |      |      |                 |
| Etanercept                    | −0.090 | 0.979 | 0.91 | 0.134, 6.225    |
| Adalimumab                    | 0.613 | 1.000 | 1.85 | 0.260, 13.098   |
| Age, years                    | −0.064 | 0.024 | 0.94 | 0.895, 0.983    |
| Male                          | 0.351 | 0.919 | 1.42 | 0.234, 8.600    |
| TNF history                   | −0.161 | 0.646 | 0.85 | 0.240, 3.023    |

Notes.
* Referent is Infliximab.
** Hosmer–Lemeshow test, Chi-square <0.0001, df = 1, $P = 1.000$.
*** Hosmer–Lemeshow test, Chi-square = 9.670, df = 8, $P = 0.289$.

Figure 2  Outcomes of different anti-TNF agents stratified by the top three disease states, 2010–2011.
DISCUSSION

At V ASDHS, patients initiated on an anti-TNF agent had a high proportion classified as responder (responder and partial responder) after 12 months of therapy. Reports from several clinical studies support this observation. Weinblatt et al. (2003) reported that 67% of patients randomized into adalimumab 40 mg every 2 weeks plus methotrexate for RA achieved American College of Rheumatology 20% (ACR20) at 24-week follow-up (Weinblatt et al., 2003). Kameda et al. (2010) reported that 90% of patients randomized into etanercept 25 mg twice weekly for RA achieved ACR20 at 24-week follow-up (Kameda et al., 2010). Colombel et al. (2010) investigated the efficacy of infliximab 5 mg per kg plus azathioprine in CD over a 30 week period and reported a remission rate of 57% (Colombel et al., 2010). Sandborn et al. (2007b) evaluated the long-term effectiveness of adalimumab 40 mg weekly and 40 mg every other week over 56 weeks in moderate-to-severe CD (Sandborn et al., 2007b). Remission was maintained in 83% and 79% of patients taking adalimumab 40 mg weekly and adalimumab 40 mg every other week, respectively (Sandborn et al., 2007b).

Ng, Chu & Khan (2013) performed a retrospective cohort study of biologic utilization for RA in the VA population from 1999 to 2009 (Ng, Chu & Khan, 2013). Biologics used as the first DMARD increased from 3% in 1999–2001 to 6.7% in 2006–2007 ($P < 0.001$) (Ng, Chu & Khan, 2013). However, the proportion of patients who had a biologic dispensed for RA was stable over the years ranging from 18.6% to 26.7% (Ng, Chu & Khan, 2013). We reported that 17% of patients who initiated etanercept previously had been on an anti-TNF agent; and 90% of patients who were initiated on adalimumab at VASDHS had previous experience with an anti-TNF agent. We adjusted for this in the logistic regression model and found that there was no significant confounding with previous history of anti-TNF agent use on the exposure-outcome relationship. A concern with previous anti-TNF agent use is confounding by indication where patients are inherently different due to severity of their disease which results in residual confounding (Salas, Hofman & Stricker, 1999). Future studies will need to address whether previous history of anti-TNF therapy has an impact on outcomes at 12 months follow up.

Utilization of anti-TNF agents in the CD veteran population has not been previously performed. However, an evaluation of hospitalization associated with CD in veterans was performed by Sonnenberg and colleagues (Sonnenberg, Richardson & Abraham, 2009). From 1975 to 2006, the total number of hospitalizations associated with CD among veterans was 54,271 with the highest proportion in the 54–64 year age group ($N = 22,551$) (Sonnenberg, Richardson & Abraham, 2009). The incidence rate for hospitalization was 11.63 per 1 million population (Sonnenberg, Richardson & Abraham, 2009). Among the veteran population, CD is a moderately severe chronic disease that has modest resource consumption. However, the use of anti-TNF agents increases the overall direct costs associated with CD. Our results provide real world effectiveness of anti-TNF agents on CD in the veteran population; however, we did not evaluate whether the strategy was based on a top-down or step-up approach (D’Haens, 2009; Hanauer, 2003; Lin, Blonski & Lichtenstein, 2010). Debate continues on whether a top-down approach is more effective.
and efficient relative to a step-up approach for CD treatment and management (D’Haens, 2009; Hanauer, 2003; Lin, Blonski & Lichtenstein, 2010).

We reported on anti-TNF agent use across a wide spectrum of different indications. We also presented the effectiveness of anti-TNF agents for the top three indications: RA, CD, and psoriasis, but small sample size prevented us from performing additional statistical tests. The high proportion of patients who were responders for RA, CD, and psoriasis provide some support for the effectiveness of anti-TNF agents at 12 months which parallels the results of other studies (Breedveld et al., 2006; Colombel et al., 2010; Colombel et al., 2007; Kameda et al., 2010; Sandborn et al., 2007b; Weinblatt et al., 2003; Weinblatt et al., 1999). Justification for using anti-TNF agents for these three indications will require a more robust analysis with a larger veteran population along with cost-effectiveness analyses.

Developing infection is a risk associated with using anti-TNF agents. Lane, et al. reported that VA patients using anti-TNF agents for RA from 1998 to 2005 were at risk of being hospitalized for an infection [Hazard Ratio (HR) = 1.24; 95% CI [1.02, 1.50]] (Lane et al., 2011). Ford & Peyrin-Biroulet (2013) reported that patients using anti-TNF agents for CD had higher risk of developing an opportunistic infection compared to placebo [Relative Risk (RR) = 2.05; 95% CI [1.10, 3.85]] (Ford & Peyrin-Biroulet, 2013). The risk of developing Mycobacterium tuberculosis was higher but not significant in patients receiving anti-TNF agents compared to placebo (RR = 2.52; 95% CI [0.62, 10.21]) (Ford & Peyrin-Biroulet, 2013). We reported that patients on etanercept and adalimumab developed infections; however, these did not require hospitalizations and were treated with oral antibiotics in the outpatient setting. Furthermore, two infection-related adverse events resulted in discontinuation of the anti-TNF agents. Lane et al. (2011) reported that patients receiving infliximab for RA had a higher hazard of hospitalized infections relative to etanercept (HR = 1.51; 95% CI [1.14, 2.00]); and patients receiving adalimumab had a lower but non-significant hazard of hospitalized infections relative to etanercept (HR = 0.95; 95% CI [0.68, 1.33]) (Lane et al., 2011). In our study, we reported that patients in the adalimumab group had more infections compared to the etanercept group; and no infections were reported in the infliximab group. This conflict may be due to the small sample size which potentially introduces type II error. Furthermore, Lane et al. (2011) focused on hospitalized infections in RA while our report described non-hospitalized infection events for all anti-TNF agent indications. In our study, stratifying by RA, we observed that 2 out of 7 patients receiving adalimumab developed an infection; however, infections were not observed in the other groups for RA (data not presented). Future studies will need to incorporate a larger sample size in order to capture any infection events stratified by disease.

Our study has limitations that are inherent to observational studies and studies involving chart reviews. This was a retrospective study that used manual chart reviews to abstract the relevant data. Consequently, there may be some validity issues with how responders and non-responders were determined. Published studies use standardized and validated criteria (ACR, DAS, and CDAI) to generate an objective score for a disease.
(e.g., RA and CD). However, in practice, these criteria may not always be used or may be impractical. As a result, manual chart reviews are often necessary to determine response to therapy. Previous studies have demonstrated that manual chart reviews may be more sensitive in identifying cases of RA compared to using electronic medical record or ICD-9 coding (Liao et al., 2010; Love, Cai & Karlson, 2011; Tinoco et al., 2011). However, interpretation of the meaning and intention of the chart notes require careful attention to the signs and symptoms of disease and improvement in patient functionality. Misclassification may pose a potential source of internal validity; therefore, we took precautions and used two independent chart reviewers to mitigate this problem. This example highlights an important limitation with using chart review in determining response. Due to a lack of objective reporting, evaluation of success with anti-TNF agents would be reduced to evaluation based on a case definition of response. We acknowledge that misclassification is an important bias that cannot be truly ruled out. Ideally, an objective measurement should be recorded in the patient's chart; however, this has not been a requirement for reimbursement or continuation of anti-TNF agents. Future policy development may consider this as a need in order to accurately report response in patients receiving these costly agents.

We focused on a single site, which may not be generalizable to other VA institutions. Although each VA medical center abides by the VHA National Formulary, differences in practice may exist at individual sites. A lack of a VA national criteria or guideline for anti-TNF agents in RA and CD has led some sites to develop their own local criteria for use. These criteria may differ resulting in a variety of methods for providers to get access to anti-TNF agents for prescribing. In addition, our study focused on a single VA medical center population which limits generalizability to the general veteran population. Future studies will need to incorporate the entire VA population using anti-TNF agents to confirm our findings.

This study had missing data, which is a concern, especially if the missing data is informative. We chose to assume that the missing data was not informative. This does not rule out the possibility that bias exists. Caution should be applied when extrapolating what potential effect these missing data would have on the overall conclusion of this observational study.

Patients who were categorized as non-responders could have been switched to another anti-TNF agent, continued on the anti-TNF agent, or discontinued altogether. It was not possible to establish the average time that these patients were on an anti-TNF agent due to these issues. We reported that the average time to follow up was 86 days, which may not reflect the average follow up in the community. Further observational studies should evaluate the average time to follow up with anti-TNF agents in order to establish the optimal time to measure efficacy and safety.

We reported that several patients were on DMARDs at baseline. However, due to the small sample size, we were unable to evaluate whether they were meaningful differences with this population in terms of effectiveness and safety. Future studies should investigate
this population and whether increased effectiveness or worsening side effect profile is reported.

Finally, patients at the VA may have dual care with non-VA medical centers and providers. These patients may have experienced changes in their therapy and received treatment for infections that were not captured with the VA electronic records. Clinical trials have reported the proportion of patients with infections ranging from 5.7% (Emery et al., 2009) to 46% (Colombel et al., 2010). To complicate matters, patient healthcare benefits may not be restricted to the VA resulting in patients “shopping” for different providers. This may lead to vital information about the patient’s disease and status that are not shared with the VA (Nayar et al., 2013a; Nayar et al., 2013b; Weeks, Yano & Rubenstein, 2002). As a result, there may be some underreporting of infection events with our analysis.

We did not observe golimumab and certolizumab pegol utilization at VASDHS between 2010 and 2011, despite their availability. We speculate that this was due to their novelty, lack of provider experience, and availability of alternative biologic agents (e.g., IL-6 inhibitors and integrin inhibitors). Although these other anti-TNF agents were not used at VASDHS, it is possible that they may have been utilized at different VA facilities. Future studies will need to expand this investigation to include more VA facilities in order to capture golimumab and certolizumab pegol utilization.

CONCLUSION

A majority of patients who were initiated with an anti-TNF agent in the VA were categorized as responders at 12 months follow-up. This was observed for RA and CD indications. Infections were only observed in etanercept and adalimumab patients; however, low sample size in the infliximab subgroup may introduce type II error. Future studies will need to investigate the entire VA population using anti-TNF agents to determine if response is consistent with those reported at VASDHS.

ADDITIONAL INFORMATION AND DECLARATIONS

Funding
Dr. Bounthavong has received a grant from UCB pharmaceuticals, which is the manufacturer of Cimzia (certolizumab pegol). IIS#: 002296. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Grant Disclosures
The following grant information was disclosed by the authors:
IIS#: 002296.

Competing Interests
Dr. Bounthavong has received a grant from UCB pharmaceuticals, which is the manufacturer of Cimzia (certolizumab pegol). Drs. Madkour and Kazerooni declare that there are no conflicts of interest regarding the publication of this article. The views and opinions of the authors do not reflect those of the US Department of Veterans Affairs.
Author Contributions

- Mark Bounthavong conceived and designed the experiments, performed the experiments, analyzed the data, contributed materials/analysis tools, wrote the paper, prepared figures and/or tables, reviewed drafts of the paper, design, chart review, analysis, and writing.
- Nermeen Madkour contributed materials/analysis tools, wrote the paper, reviewed drafts of the paper, design, chart review, and writing.
- Rashid Kazerooni contributed materials/analysis tools, wrote the paper, reviewed drafts of the paper, writing.

Ethics

The following information was supplied relating to ethical approvals (i.e., approving body and any reference numbers):

UCSD/Veterans Affairs San Diego Healthcare System Research and Development Institutional Review Board Protocol #: H120150.

REFERENCES

Agarwal SK. 2011a. Core management principles in rheumatoid arthritis to help guide managed care professionals. Journal of Managed Care Pharmacy 17:S03–S08.

Agarwal SK. 2011b. Biologic agents in rheumatoid arthritis: an update for managed care professionals. Journal of Managed Care Pharmacy 17:S14–S18.

Ancuța C, Ancuța E, Miu S, Iordache C, Belibou C, Chirieac R. 2009. Adalimumab therapy in patients with active rheumatoid arthritis. Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 113:710–715.

Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, Genovese MC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Finck BK. 2000. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. New England Journal of Medicine 343:1586–1593 DOI 10.1056/NEJM200011303432201.

Baumgart DC, Sandborn WJ. 2012. Crohn's disease. Lancet 380:1590–1605 DOI 10.1016/S0140-6736(12)60026-9.

Bodger K. 2002. Cost of illness of Crohn’s disease. PharmacoEconomics 20:639–652 DOI 10.2165/00019053-200220100-00001.

Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, Sharp J, Perez JL, Spencer-Green GT. 2006. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis and Rheumatism 54:26–37 DOI 10.1002/art.21519.

Choy E, McKenna F, Vencovsky J, Valente R, Goel N, Vanlunen B, Davies O, Stahl H-D, Alten R. 2012. Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. Rheumatology 51:1226–1234 DOI 10.1093/rheumatology/ker519.
Colombel J-F, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz D, Lichtiger S, D’Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, Rutgeerts P. 2010. Infliximab, azathioprine, or combination therapy for Crohn’s disease. New England Journal of Medicine 362:1383–1395 DOI 10.1056/NEJMoa0904492.

Colombel J-F, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. 2007. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology 132:52–65 DOI 10.1053/j.gastro.2006.11.041.

D’Haens GR. 2009. Top-down therapy for Crohn’s disease: rationale and evidence. ACTA Clinica Belgica 64:540–546 DOI 10.2143/ACB.64.6.1002534.

Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougdas M, Robertson D, Pedersen R, Koenig AS, Freundlich B. 2010. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis and Rheumatism 62:674–682 DOI 10.1002/art.27268.

Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, Nash P, Amante EJB, Churchill M, Park W, Pons-Estel BA, Doyle MK, Visvanathan S, Xu W, Rahman MU. 2009. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. Arthritis and Rheumatism 60:2272–2283 DOI 10.1002/art.24638.

FDA Office of the Commissioner. 2008. FDA approves cimzia to treat Crohn’s disease. Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2008/ucm116882.htm (accessed 23 June 13).

Feagan BG, Coteur G, Tan S, Keininger DL, Schreiber S. 2009. Clinically meaningful improvement in health-related quality of life in a randomized controlled trial of certolizumab pegol maintenance therapy for Crohn’s disease. American Journal of Gastroenterology 104:1976–1983 DOI 10.1038/ajg.2009.199.

Ford AC, Peyrin-Biroulet L. 2013. Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. American Journal of Gastroenterology 108(8):1268–1276 DOI 10.1038/ajg.2013.138.

Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P. 2011. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. American Journal of Gastroenterology 106:644–659 quiz 660 DOI 10.1038/ajg.2011.73.

Gabriel SE, Michaud K. 2009. Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases. Arthritis Research & Therapy 11(3):229 DOI 10.1186/ar2669.

Hanauer SB. 2003. Crohn’s disease: step up or top down therapy. Best Practice & Research Clinical Gastroenterology 17:131–137 DOI 10.1053/bega.2003.0361.

Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. 2006. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology 130:323–333 DOI 10.1053/j.gastro.2005.11.030.
Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, Liang MH, Kremer HM, Mayes MD, Merkel PA, Pillemer SR, Reveille JD, Stone JH, National Arthritis Data Workgroup. 2008. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis and Rheumatism* 58:15–25 DOI 10.1002/art.23177.

Hou JK, Kramer JR, Richardson P, Mei M, El-Serag HB. 2013. The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study. *Inflammatory Bowel Diseases* 19:1059–1064 DOI 10.1097/MIB.0b013e31828028ca.

Kameda H, Ueki Y, Saito K, Nagaoka S, Hidaka T, Atsumi T, Tsukano M, Kasama T, Shiozawa S, Tanaka Y, Takeuchi T. 2010. Etanercept (ETN) with methotrexate (MTX) is better than ETN monotherapy in patients with active rheumatoid arthritis despite MTX therapy: a randomized trial. *Modern Rheumatology* 20:531–538 DOI 10.3109/s10165-010-0324-4.

Kappelman MD, Rifas-Shiman SL, Porter CQ, Ollendorf DA, Sandler RS, Galanko JA, Finkelstein JA. 2008. Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology* 135:1907–1913 DOI 10.1053/j.gastro.2008.09.012.

Keystone E, Van Der Heijde D, Mason Jr D, Landewé R, Van Vollenhoven R, Combe B, Emery P, Strand V, Mease P, Desai C, Pavelka K. 2008. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis and Rheumatism* 58:3319–3329 DOI 10.1002/art.23964.

Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae S-C, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU. 2009. Golimumab, a human antibody to tumour necrosis factor α given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Annals of the Rheumatic Diseases* 68:789–796 DOI 10.1136/ard.2008.099010.

Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, Fischkoff SA, Chartash EK. 2004. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis and Rheumatism* 50:1400–1411 DOI 10.1002/art.20217.

Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, Martín Mola E, Pavelka K, Sany J, Settas L, Wajdula J, Pedersen R, Fatenejad S, Sanda M, TEMPO (Trial of Etanercept and Methotrexate with Radiographic Patient Outcomes) study investigators. 2004. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 363:675–681 DOI 10.1016/S0140-6736(04)15640-7.

Lane MA, McDonald JR, Zeringue AL, Caplan L, Curtis JR, Ranganathan P, Eisen SA. 2011. TNF-α antagonist use and risk of hospitalization for infection in a national cohort of veterans with rheumatoid arthritis. *Medicine* 90:139–145 DOI 10.1097/MD.0b013e31821106a.

Lee TA, Shields AE, Vogeli C, Gibson TB, Woong-Sohn M, Marder WD, Blumenthal D, Weiss KB. 2007. Mortality rate in veterans with multiple chronic conditions. *Journal of General Internal Medicine* 22(Suppl 3):403–407 DOI 10.1007/s11606-007-0277-2.
Liao KP, Cai T, Gainer V, Goryachev S, Zeng-treitler Q, Raychaudhuri S, Szolovits P, Churchill S, Murphy S, Kohane I, Karlson EW, Plenge RM. 2010. Electronic medical records for discovery research in rheumatoid arthritis. Arthritis Care and Research 62:1120–1127 DOI 10.1002/acr.20184.

Lichtenstein GR, Hanauer SB, Sandborn WJ, Practice Parameters Committee of American College of Gastroenterology. 2009. Management of Crohn’s disease in adults. American Journal of Gastroenterology 104:465–483 DOI 10.1038/ajg.2008.168.

Lin MV, Blonski W, Lichtenstein GR. 2010. What is the optimal therapy for Crohn’s disease: step-up or top-down? Expert Review of Gastroenterology and Hepatology 4:167–180 DOI 10.1586/egh.10.4.

Little RJA, Rubin DB. 2002. Statistical analysis with missing data, Second edition. Hoboken, NJ: John Wiley & Sons, Inc.

Loftus CG, Loftus Jr EV, Harmsen WS, Zinsmeister AR, Tremaine WJ, Melton 3rd LJ, Sandborn WJ. 2007. Update on the incidence and prevalence of Crohn’s disease and ulcerative colitis in Olmsted County, Minnesota, 1940–2000. Inflammatory Bowel Diseases 13:254–261 DOI 10.1002/ibd.20029.

Loftus Jr EV, Schoenfeld P, Sandborn WJ. 2002. The epidemiology and natural history of Crohn’s disease in population-based patient cohorts from North America: a systematic review. Alimentary Pharmacology and Therapeutics 16:51–60 DOI 10.1046/j.1365-2036.2002.01140.x.

Loomes DE, Teshima C, Jacobs P, Fedorak RN. 2011. Health care resource use and costs in Crohn’s disease before and after infliximab therapy. Canadian Journal of Gastroenterology 25:497–502.

Louis E, Löfberg R, Reinsch W, Camez A, Yang M, Pollack PF, Chen N, Chao J, Mulani PM. 2013. Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn’s disease: results from the CARE trial. Journal of Crohn’s and Colitis 7:34–43 DOI 10.1016/j.crohns.2012.02.017.

Love TJ, Cai T, Karlson EW. 2011. Validation of psoriatic arthritis diagnoses in electronic medical records using natural language processing. Seminars in Arthritis and Rheumatism 40:413–420 DOI 10.1016/j.semarthrit.2010.05.002.

Lundkvist J, Kastäng F, Kobelt G. 2008. The burden of rheumatoid arthritis and access to treatment: health burden and costs. The European Journal of Health Economics 8(Suppl 2):S49–S60 DOI 10.1007/s10198-007-0088-8.

Maini RN, St Clair EW, Breedveld F, Forst D, Kalden J, Weisman M, Smolen J, Emery P, Harriman G, Feldmann M, Lipsky P. 1999. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354:1932–1939 DOI 10.1016/S0140-6736(99)05246-0.

Mayberry JF, Lobo A, Ford AC, Thomas A. 2013. NICE clinical guideline (CG152): the management of Crohn’s disease in adults, children and young people. Alimentary Pharmacology and Therapeutics 37:195–203 DOI 10.1111/apt.12102.

Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, Weaver AL, Keystone EC, Forst DE, Mease PJ, Ruderman EM, Horwitz DA, Arkfeld DG, Garrison L, Burge DJ, Blosch CM, Lange ML, McDonnell ND, Weinblatt ME. 1999. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Annals of Internal Medicine 130:478–486 DOI 10.7326/0003-4819-130-6-199903160-00004.
Nayar P, Apenteng B, Yu F, Woodbridge P, Fetrick A. 2013a. Rural veterans’ perspectives of dual care. *Journal of Community Health* 38:70–77 DOI 10.1007/s10900-012-9583-7.

Nayar P, Nguyen AT, Ojha D, Schmid KK, Apenteng B, Woodbridge P. 2013b. Transitions in dual care for veterans: non-federal physician perspectives. *Journal of Community Health* 38:225–237 DOI 10.1007/s10900-012-9604-6.

Ng B, Chu A, Khan MM. 2013. A retrospective cohort study: 10-year trend of disease-modifying antirheumatic drugs and biological agents use in patients with rheumatoid arthritis at Veteran Affairs Medical Centers. *BMJ Open* 3:e002468 DOI 10.1136/bmjopen-2012-002468.

National Digestive Diseases Information Clearinghouse (NDDIC). 2013. Crohn’s Disease. Available at [http://www.digestive.niddk.nih.gov/ddiseases/pubs/crohns/index.aspx#treatment](http://www.digestive.niddk.nih.gov/ddiseases/pubs/crohns/index.aspx#treatment) (accessed 23 June 2013).

Nixon RM, Bansback N, Brennan A. 2007. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. *Statistics in Medicine* 26:1237–1254 DOI 10.1002/sim.2624.

Ordás I, Feagan BG, Sandborn WJ. 2011. Early use of immunosuppressives or TNF antagonists for the treatment of Crohn’s disease: time for a change. *Gut* 60:1754–1763 DOI 10.1136/gutjnl-2011-300934.

Salas M, Hofman A, Stricker BH. 1999. Confounding by indication: an example of variation in the use of epidemiologic terminology. *American Journal of Epidemiology* 149:981–983 DOI 10.1093/oxfordjournals.aje.a009758.

Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S. 2007a. Certolizumab pegol for the treatment of Crohn’s disease. *New England Journal of Medicine* 357:228–238 DOI 10.1056/NEJMoa067594.

Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. 2007b. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. *Gut* 56:1232–1239 DOI 10.1136/gut.2006.106781.

Segal B, Rhodus NL, Patel K. 2008. Tumor necrosis factor (TNF) inhibitor therapy for rheumatoid arthritis. *Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology* 106:778–787 DOI 10.1016/j.tripleo.2008.07.025.

Singh JA, Cameron DR. 2012. Summary of AHRQ’s comparative effectiveness review of drug therapy for rheumatoid arthritis (RA) in adults–an update. *Journal of Managed Care Pharmacy* 18:S1–S18.

Sonnenberg A, Richardson PA, Abraham NS. 2009. Hospitalizations for inflammatory bowel disease among US military veterans 1975–2006. *Digestive Diseases and Sciences* 54:1740–1745 DOI 10.1007/s10620-009-0764-x.

St Clair EW, van der Heijde DMFM, Smolen JS, Maini RN, Bathon JM, Emery P, Keystone E, Schiff M, Kalden JR, Wang B, Dewoody K, Weiss R, Baker D, Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. 2004. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis and Rheumatism* 50:3432–3443 DOI 10.1002/art.20568.

Staples MP, March L, Lassere M, Reid C, Buchbinder R. 2011. Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database. *Rheumatology* 50:166–175 DOI 10.1093/rheumatology/keq322.
Tinoco A, Evans RS, Staes CJ, Lloyd JF, Rothschild JM, Haug PJ. 2011. Comparison of computerized surveillance and manual chart review for adverse events. *Journal of the American Medical Informatics Association* **18**:491–497 DOI 10.1136/amiajnl-2011-000187.

Van de Putte LBA, Atkins C, Malaise M, Sany J, Russell AS, van Riel PLCM, Settas L, Bijlsma JW, Todesco S, Dougados M, Nash P, Emery P, Walter N, Kaul M, Fischko S, Kupper H. 2004. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Annals of the Rheumatic Diseases* **63**:508–516 DOI 10.1136/ard.2003.013052.

Van der Heijde D, Klareksog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, Tornero-Molina J, Wajdula J, Pedersen R, Fatenejad S, TEMPO Study Investigators. 2006. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis and Rheumatism* **54**:1063–1074 DOI 10.1002/art.21655.

Van der Valk ME, Mangen MJ, Leenders M, Dijkstra G, van Bodegraven AA, Fidder HH, de Jong DJ, Pierik M, van der Woude CJ, Clemens CH, Jansen JM, Mahmmod N, van de Meeberg PC, van der Meulen-de Jong AE, Ponsioen CY, Bolwerk CJ, Vermeijden JR, Siersema PD, van Oijen MG, Oldenburg B, COIN study group and the Dutch Initiative on Crohn and Colitis. 2014. Healthcare costs of inflammatory bowel disease have shifted from hospitalisation and surgery towards anti-TNFα therapy: results from the COIN study. *Gut* **63**(1):72–79 DOI 10.1136/gutjnl-2012-303376.

Weeks WB, Yano EM, Rubenstein LV. 2002. Primary care practice management in rural and urban Veterans Health Administration settings. *The Journal of Rural Health* **18**:298–303 DOI 10.1111/j.1748-0361.2002.tb00890.x.

Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Feusner JH, Birbara CA, Teoh LA, Fischko S, Chartash EK. 2003. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis and Rheumatism* **48**:35–45 DOI 10.1002/art.10697.

Weinblatt ME, Kremer JM, Bankhurst AD, Bulitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. 1999. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *New England Journal of Medicine* **340**:253–259 DOI 10.1056/NEJM199901283400401.